Targeting tumor-associated macrophages in an orthotopic murine model of diffuse malignant mesothelioma

被引:85
|
作者
Miselis, Nathan R. [1 ]
Wu, Zhijin J. [2 ]
Van Rooijen, Nico [3 ]
Kane, Agnes B. [1 ]
机构
[1] Brown Univ, Dept Pathol & Lab Med, Providence, RI 02912 USA
[2] Brown Univ, Ctr Stat Sci, Providence, RI 02912 USA
[3] Free Univ Amsterdam, Dept Mol Cell Biol, Med Ctr, Amsterdam, Netherlands
关键词
D O I
10.1158/1535-7163.MCT-07-0579
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Tumors are a mixture of neoplastic and host stromal cells, which establish a microenvironment that contributes to tumor progression. In this study, the contribution of tumor-associated macrophages (TAMs) to tumor growth and metastasis was examined using an orthotopic, immunocompetent murine model of diffuse malignant peritoneal mesothelioma. The expression profile of cytokines and chemokines in solid tumors was consistent with a M2-polarized, TAM-mediated immunosuppressive microenvironment. TAMs were targeted using liposome-encapsulated clodronate (CLIP). Exposure of tumor spheroids to CM-Dil-labeled CLIP in situ confirms targeting of macrophages and not mesothelioma cells. Intraperitoneal (i.p.) delivery of CLIP produced apoptosis in tumor spheroids and solid tumors in contrast to delivery of liposome-encapsulated PBS or PBS. Mice received an i.p. injection of mesothelioma cells with CLIP delivered i.p. every 5 days. This treatment protocol produces a 4-fold reduction in the number of tumors, a 17-fold reduction in the relative tumor burden, and a 5-fold reduction in invasion and metastasis when compared with mice exposed to liposome-encapsulated PBS or PBS. Following transplantation of tumor spheroids and treatment with CLIP, mice showed a 4-fold reduction in the number of tumors and a 15-fold reduction in relative tumor burden. Mice bearing established tumors showed a 2-fold reduction in the number of tumors and relative tumor burden when exposed to half the previous dose of CLIP delivered by repeated i.p. injection. These reductions in tumor burden are statistically significant and identify TAMs as an important host-derived cell that contributes to growth, invasion, and metastasis in diffuse malignant peritoneal mesothelioma.
引用
收藏
页码:788 / 799
页数:12
相关论文
共 50 条
  • [21] Targeting tumor-associated macrophages for cancer treatment
    Mengjun Li
    Linye He
    Jing Zhu
    Peng Zhang
    Shufang Liang
    Cell & Bioscience, 12
  • [22] Tailoring Nanomaterials for Targeting Tumor-Associated Macrophages
    Ovais, Muhammad
    Guo, Mengyu
    Chen, Chunying
    ADVANCED MATERIALS, 2019, 31 (19)
  • [23] Targeting tumor-associated macrophages for cancer treatment
    Li, Mengjun
    He, Linye
    Zhu, Jing
    Zhang, Peng
    Liang, Shufang
    CELL AND BIOSCIENCE, 2022, 12 (01):
  • [24] Tailoring nanomaterials for targeting tumor-associated macrophages
    Ovais, M.
    Guo, M.
    Chen, C.
    EUROPEAN JOURNAL OF IMMUNOLOGY, 2019, 49 : 534 - 534
  • [25] Targeting tumor-associated macrophages for cancer immunotherapy
    Shu, Yongheng
    Cheng, Ping
    BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, 2020, 1874 (02):
  • [26] Targeting tumor-associated macrophages as an antitumor strategy
    Cheng, Nan
    Bai, Xuexia
    Shu, Yuxin
    Ahmad, Owais
    Shen, Pingping
    BIOCHEMICAL PHARMACOLOGY, 2021, 183
  • [27] Targeting Tumor-Associated Macrophages for Cancer Therapy
    Yumul, Roma
    Richter, Maximilian
    Giovani, Michelle
    Kasahara, Noriyuki
    Lieber, Andre
    MOLECULAR THERAPY, 2014, 22 : S256 - S256
  • [28] M2-like tumor-associated macrophages may promote tumor progression in malignant pleural mesothelioma
    Fukui, Tetsuya
    Sumitomo, Ryota
    Menju, Toshi
    Kobayashi, Masashi
    Sakai, Hiroaki
    Date, Hiroshi
    TRANSLATIONAL ONCOLOGY, 2025, 54
  • [29] Targeting Tumor-Associated Macrophages in the Pediatric Sarcoma Tumor Microenvironment
    Koo, Jane
    Hayashi, Masanori
    Verneris, Michael R.
    Lee-Sherick, Alisa B.
    FRONTIERS IN ONCOLOGY, 2020, 10
  • [30] Targeting immune checkpoints on tumor-associated macrophages in tumor immunotherapy
    Xu, Shumin
    Wang, Chenyang
    Yang, Lingge
    Wu, Jiaji
    Li, Mengshu
    Xiao, Peng
    Xu, Zhiyong
    Xu, Yun
    Wang, Kai
    FRONTIERS IN IMMUNOLOGY, 2023, 14